Solving the puzzle of what makes immunotherapies work
- PMID: 35933298
- PMCID: PMC10109520
- DOI: 10.1016/j.trecan.2022.06.011
Solving the puzzle of what makes immunotherapies work
Abstract
The rapid adoption of immune checkpoint blockade (ICB) therapies has led to a need to understand the mechanistic drivers of efficacy and the identification of novel biomarkers that enrich for patients who benefit from ICB therapy. Here, we provide a perspective on emerging biomarker candidates, their underlying biological mechanisms, and how they may fit into the current landscape of ICB biomarkers. We discuss new frameworks to identify and evaluate biomarker candidates and review the opportunities and challenges of utilizing biomarker-derived models to facilitate the development of new immunotherapies.
Keywords: biomarker; immune checkpoint blockade; immunotherapy; tumor immunology.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests T.A.C. is a cofounder of Gritstone Oncology and holds equity. T.A.C. also holds equity in An2H and acknowledges grant funding from Bristol Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai. T.A.C. has served as an advisor for Bristol Myers, MedImmune, Squibb, Illumina, Eisai, AstraZeneca, and An2H. T.A.C. is the inventor on intellectual property held by Memorial Sloan Kettering Cancer Center on using tumor mutation burden to predict immunotherapy response, with pending patent, which has been licensed to Personal Genome Diagnostics. X.M. has no interests to declare.
Figures


Similar articles
-
Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance.Front Immunol. 2022 Sep 15;13:915094. doi: 10.3389/fimmu.2022.915094. eCollection 2022. Front Immunol. 2022. PMID: 36189283 Free PMC article. Review.
-
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.Curr Treat Options Oncol. 2021 Mar 20;22(5):38. doi: 10.1007/s11864-021-00833-4. Curr Treat Options Oncol. 2021. PMID: 33743085 Review.
-
Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.Front Immunol. 2022 Jan 11;12:810388. doi: 10.3389/fimmu.2021.810388. eCollection 2021. Front Immunol. 2022. PMID: 35087529 Free PMC article. Review.
-
Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.Front Immunol. 2020 Sep 30;11:568759. doi: 10.3389/fimmu.2020.568759. eCollection 2020. Front Immunol. 2020. PMID: 33117354 Free PMC article. Review.
-
Combination immunotherapy strategies for glioblastoma.J Neurooncol. 2021 Feb;151(3):375-391. doi: 10.1007/s11060-020-03481-0. Epub 2021 Feb 21. J Neurooncol. 2021. PMID: 33611705 Review.
Cited by
-
CSTF2-impeded innate αβ T cell infiltration and activation exacerbate immune evasion of pancreatic cancer.Cell Death Differ. 2025 May;32(5):973-988. doi: 10.1038/s41418-025-01464-0. Epub 2025 Feb 19. Cell Death Differ. 2025. PMID: 39972059
-
New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.Mol Cancer. 2023 Mar 2;22(1):43. doi: 10.1186/s12943-023-01751-9. Mol Cancer. 2023. PMID: 36859240 Free PMC article. Review.
-
Sequential Chromogenic IHC: Spatial Analysis of Lymph Nodes Identifies Contact Interactions between Plasmacytoid Dendritic Cells and Plasmablasts.Cancer Res Commun. 2023 Jul 13;3(7):1237-1247. doi: 10.1158/2767-9764.CRC-23-0102. eCollection 2023 Jul. Cancer Res Commun. 2023. PMID: 37484199 Free PMC article.
-
Establishing a model composed of immune-related gene-modules to predict tumor immunotherapy response.Sci Rep. 2024 Jul 18;14(1):16630. doi: 10.1038/s41598-024-67742-y. Sci Rep. 2024. PMID: 39025898 Free PMC article.
-
Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer.Nat Commun. 2024 Feb 19;15(1):1515. doi: 10.1038/s41467-024-45479-6. Nat Commun. 2024. PMID: 38373991 Free PMC article.
References
-
- E.B G. (2010) Encyclopedia of Perception (Vol. 1, SAGE Publications
-
- Whitson AR and Walster HL (1912) Soils and soil fertility Webb publishing co.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources